Capital

Three EU Deep-Tech Bets Skip Pure Venture Capital

Oceanloop, Computomics and LITILIT all raised capital this week - and each leaned on EIB debt, InvestEU backing or a national development-bank loan instead of pure venture equity.

CapitalBy Servola Tech Desk2026-08-195 min read

AI-assisted, edited by humans. | Editor-in-Chief: Leon Soliman | Editorial standards

Three EU Deep-Tech Bets Skip Pure Venture Capital

Key takeaways

Oceanloop's EUR 38.5 million round is anchored by a EUR 32 million European Investment Bank venture-debt facility, not fresh equity - proof that debt, not dilution, is funding Europe's hardest physical-technology bets.
Computomics closed a EUR 6.3 million Series B led by Convent Capital's Agri Food Fund, with High-Tech Gruenderfonds, MBG Baden-Wuerttemberg and Amathaon Capital participating, backstopped by the EU's InvestEU program.
LITILIT's entire EUR 8 million raise, against a EUR 10 million total project, is a loan from ILTE financed by INVEGA, Lithuania's national development bank - no venture fund appears in the round at all.
eu-startups.com reported all three deals within about 24 hours of each other in mid-August 2026, across three unrelated sectors: aquaculture, agri-climate machine learning and precision laser manufacturing.
For capital-intensive, long-horizon technology, public development-bank instruments are a deliberate financing choice for European founders to plan around, not a fallback for companies that could not raise venture equity.

Three Raises, One Week, One Pattern

On the outskirts of Munich, recirculating tanks hold Giant Grouper being raised at industrial scale - a fish that has mostly been imported live from Southeast Asia until now, growing instead in land-based aquaculture systems built by Oceanloop.

This week, eu-startups.com reported not one but three separate European deep-tech financing rounds within about 24 hours: Oceanloop's facility of up to EUR 38.5 million, Computomics' EUR 6.3 million Series B, and LITILIT's EUR 8 million loan. On the surface, they have nothing in common - aquaculture technology, climate-adaptive crop-breeding software, and precision laser manufacturing.

Look past the sector and at the capital structure, and a pattern appears: none of the three companies raised money the way a typical venture-backed software company would. Each reached, in a different proportion, for public development-bank capital rather than relying on venture equity alone.

Oceanloop: EIB Debt Carries the Load

Oceanloop's financing totals, as reported, up to EUR 38.5 million, and only part of it is equity: Hatch Blue's Blue Revolution Fund and Stolt Ventures. The larger piece, a EUR 32 million venture-debt facility, comes from the European Investment Bank. That facility is not new: it was originally signed in October 2024, and eu-startups.com reported it was amended and expanded in July 2026.

What matters more than the headline: a EUR 32 million debt facility from the EIB, sized to fund physical RAS infrastructure and scale-up rather than working capital, carries most of the weight in Oceanloop's round, while the equity investors add a smaller, higher-risk slice alongside it. For land-based aquaculture, a capital-intensive build with a long path to full-scale production, that mix looks deliberate rather than a sign the company could not raise pure equity.

Computomics: VC-Led, Publicly Backstopped

Computomics, a Tuebingen-based spin-off of the Max Planck Institute and the University of Tuebingen founded in 2012, builds machine-learning models that forecast how crop genotypes will perform under heat and drought stress - a tool crop breeders need more urgently now that the EU Joint Research Centre has downgraded its 2026 crop-yield forecasts. The company closed a EUR 6.3 million Series B, eu-startups.com reported, led by Convent Capital's Agri Food Fund at EUR 5 million, with High-Tech Gruenderfonds, MBG Baden-Wuerttemberg, and Amathaon Capital also participating.

What sets this round apart is not the lead investor but what sits alongside it: support from the EU's InvestEU financing program, folded into a round that is otherwise a conventional VC-led Series B. Private capital picked the company and set the terms; public capital added weight to the same round rather than replacing it. That is a different pattern from Oceanloop's, where debt carried most of the total, but it is the same instinct to bring public development capital into a deep-tech round rather than treat it as unavailable.

LITILIT: One Loan, No Venture Equity

In Vilnius, LITILIT has spent over a decade, since its founding in 2015, developing femtosecond laser systems built on patented cold-ablation technology for precision manufacturing and medical applications, with commercialization targeted for the second half of 2029. eu-startups.com reported the company has now secured EUR 8 million in financing against a total project value of EUR 10 million.

The entire EUR 8 million is a loan, not equity: it comes from ILTE, financed by INVEGA, Lithuania's national development bank. There is no venture fund named in the round at all. For a company with a multi-year runway to commercialization and a technology aimed at manufacturing and medical markets rather than software, that is the cleanest version of the pattern in this week's three deals - a national development bank underwriting the whole bridge from R&D to a commercial product.

What This Means for Your Capital Stack

Put the three deals side by side and a genuine structural difference from the US venture-equity model comes into view. Oceanloop's round is majority EIB venture debt. Computomics' round is a private Series B backstopped by InvestEU. LITILIT's round is entirely a national development-bank loan with no venture equity present. Three sectors, three different blends, one shared instinct: reach for public development-bank capital when the technology is physical, capital-intensive, and slow to reach a venture-style return.

The practical lesson for a European founder building this kind of company is to treat the EIB, InvestEU, and national development banks - Germany's regional development funds, Lithuania's INVEGA, and their equivalents elsewhere - as instruments to investigate from the start of a raise, not as a fallback after VC conversations stall. EIB venture debt tends to suit capital equipment and scale-up; national development-bank loans tend to suit the R&D-to-commercialization bridge; EU co-investment programs like InvestEU tend to sit alongside a private lead when the technology serves a recognized public policy goal. Knowing which applies to your business is part of the raise, not an afterthought.

Frequently asked questions

Is venture debt from the EIB harder to get than equity?

The EIB facility behind Oceanloop's round was not a same-week decision: it was originally signed in October 2024 and only amended and expanded in July 2026. Development-bank debt tends to move on relationship and track record rather than a single pitch, so founders should expect a longer process than a single VC check - in exchange, the scale-up capital actually available can be considerably larger.

Does taking a development-bank loan mean I could not raise venture capital?

No. Computomics' round shows the opposite: a private, VC-led Series B, with Convent Capital's Agri Food Fund writing the lead check, alongside InvestEU support in the same instrument. Public and private capital are increasingly combined rather than treated as substitutes for each other.

Which instrument fits which stage or need?

The three deals suggest a rough division: EIB venture debt suits capital equipment and scale-up, like Oceanloop's RAS facilities. EU co-investment programs like InvestEU sit alongside a private lead at Series B when the underlying technology serves a public policy goal, like climate-resilient agriculture for Computomics. National development banks like Lithuania's INVEGA fund the R&D-to-commercialization bridge for a single company's project, like LITILIT.

Do these instruments dilute my equity?

Venture debt and development-bank loans are repaid, not converted into shares, so they preserve equity in a way a VC round does not - though as with any debt, terms and covenants vary by lender and should be checked case by case.

European deep-tech does not raise money the way American venture-capital media assumes it does. This week's evidence shows a public development-bank layer working deliberately alongside or instead of venture equity, for exactly the physical, capital-intensive, long-horizon bets that pure VC structurally underfunds. Founders building this category of company should treat the EIB, InvestEU, and national development banks as a first-tier financing route, not a consolation prize.

European Investment BankInvestEUdeep techventure debtdevelopment banksEU startups

Europe's Quantum Champion Listed in New York

IQM became Europe's first publicly traded quantum company by listing on Nasdaq, raising about 226 million dollars, then slipping on day one after a prospectus that admits quantum may never reach large-scale commercial use. The signal for operators is plain.

3 min read

Capital

Africa's Largest Seed Round Just Backed A Drone Maker

Terra Industries closed a 52 million dollar seed round, the largest by an African startup, to build autonomous systems protecting 11 billion dollars in infrastructure.

3 min read

Decisions

The Third Pivot Was the Warning Magic Leap Missed

Magic Leap filed a WARN notice for 193 layoffs effective 1 October 2026, its fourth strategic pivot after $4 billion raised. The lesson is the pattern, not the pivot.

4 min read

← All articles